Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X1HE
|
|||
| Former ID |
DIB001788
|
|||
| Drug Name |
Ozenoxacin
|
|||
| Synonyms |
T-3912; GF-001001-00; Non-fluorinated quinolone (Gram positive bacterial infection), Ferrer
Click to Show/Hide
|
|||
| Indication | Impetigo [ICD-11: 1B72; ICD-10: L01, L01.0; ICD-9: 684] | Approved | [1] | |
| Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 3 | [2] | ||
| Company |
Ferrer Internacional
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21N3O3
|
|||
| Canonical SMILES |
CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C
|
|||
| InChI |
1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
|
|||
| InChIKey |
XPIJWUTXQAGSLK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 245765-41-7
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:136050
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial DNA gyrase (Bact gyrase) | Target Info | Modulator | [3] |
| DNA replication (DNA repli) | Target Info | Inhibitor | [1] | |
| Staphylococcus DNA gyrase A (Stap-coc gyrA) | Target Info | Inhibitor | [1] | |
| Staphylococcus Topoisomerase IV (Stap-coc parC) | Target Info | Modulator | [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | |||
| REF 2 | ClinicalTrials.gov (NCT02090764) Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo. U.S. National Institutes of Health. | |||
| REF 3 | In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.